| HOME >> MEDICINE >> TECHNOLOGY |
BOSTON, July 30 /PRNewswire/ -- Scimitar Equity, LLC issues a review of Generex Biotechnology Corporation (Nasdaq: GNBT), entitled, "RapidMist(TM), the Non-Invasive Oral Drug Delivery Platform, Sets the Tone as Best in Class Followed by an Expanding Pipeline and Global Revenues."
This review is available at website: http://www.scimitarequity.com.
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in Phase 3 clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.
Scimitar Equity, LLC provides sponsored equity research of emerging
healthcare companies for the investing communities. We certify that all the
views expressed in this review, accurately reflect our personal views about
Generex Biotechnology Corporation (Nasdaq: GNBT) and its or their
securities. No part of our compensation was, is, or will be, directly or
indirectly, related to the specific recommendations or views contained in
this review and we will not have any investment banking relationships or
personal investment in any sponsored company. Investors are advised that
this analysis and review is issued solely for informational purposes and is
not to be construed as an offer to sell or the solicitation of an offer to
buy. Scimitar was paid for preparing this review. This analysis and review
does not have regard to the specific investment objectives, financial
situation and the information contained herein is based on sources that we
believe to be reliable but is not guaranteed by us as being accurate and
does not purport to be a complete statement or summary of the available
data. Any opinions expressed are statements of our own judgment as of the
date of publication and are subject to change without notice. Please read
all our important disclosures.
CONTACT: Scimitar Equity, LLC
Henry W. McCusker
Director of Research
phone: (617) 559.1080
e-mail: hwm@scimitarequity.com
'/>"/>
| SOURCE Scimitar Equity, LLC Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. CEL-SCI Corporation Releases Letter to Shareholders
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |